Company Report
Last edited 7 months ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#27
Performance (52m)
-2.3% pa
Followed by
94
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Management
stale
Added 7 months ago

Get well soon Kees.


PWR Founder and Managing Director Takes Medical Leave

PWR’s Managing Director and Founder, Kees Weel, is taking temporary leave from his full-time role to seek treatment for an

acute medical condition. PWR’s Executive Leadership Team will assume Kees Weel’s day-to-day responsibilities, with Chief

Technical and Commercial Officer, Matthew Bryson, appointed by the Board to the role of Acting CEO.


Kees Weel said, “While I will remain active in PWR’s overall direction, I have advised the Board that concentrating on my

recovery is my priority. Matthew Bryson and the Executive Leadership Team have my full support, and I have complete faith that they will be able to deliver on PWR’s objectives and the move to PWR’s new headquarters, which has successfully commenced.”

PWR’s Chairman, Roland Dane said, “The Board supports Kees in his decision to focus on his health and wishes him all the best for his recovery. We look forward to welcoming him back when he is ready.”

About Matthew Bryson

Matthew joined PWR in 2000 as a design and manufacturing engineer contributing to PWR’s formative years across product and production engineering responsibilities. This role progressed to the position of Engineering Manager at PWR, as a position held

for 15 years, working closely with PWR’s customers to grow the business, and overseeing the continued development of PWR’s product and advanced manufacturing capabilities. In July 2020, Matthew commenced the position of Chief Operating Officer at

PWR, before taking on his current role of Chief Technical and Commercial Officer in August 2021 to support the future growth of PWR.

Remuneration details for Matthew Bryson are summarised below:

Length of Contract Open ended

Notice Period 6 months

Total Fixed Remuneration $420,300

Additional Remuneration for Acting CEO role $220,000

Short Term Incentive Plan Participation Up to 50% of Total Fixed Remuneration

Long Term Incentive Plan Participation Up to 50% of Total Fixed Remuneration

Matthew Bryson Sharyn Williams

Acting CEO Chief Financial Officer

+61 7 5547 1600 +61 7 5547 1600

#Risks
stale
Last edited one year ago

While there is nothing untoward about the company investing for growth in future periods, even after the drop, the valuation looks rich against a backdrop of earnings going backwards due to large capital expenditure outlays over FY25 and 26.

It seems like there is room for the multiple (50x statutory and about 40x underlying earnings) to come down.